Provided by Tiger Trade Technology Pte. Ltd.

Lixte Biotechnology Holdings Inc.

5.52
-0.3900-6.60%
Volume:105.67K
Turnover:594.68K
Market Cap:68.35M
PE:-4.80
High:6.02
Open:5.93
Low:5.30
Close:5.91
52wk High:6.26
52wk Low:0.6400
Shares:12.38M
Float Shares:11.87M
Volume Ratio:1.22
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1500
EPS(LYR):-1.2600
ROE:-140.99%
ROA:-64.50%
PB:8.60
PE(LYR):-4.38

Loading ...

LIXTE Biotechnology (NASDAQ: LIXT) Advances Lead Compound in Tumor Immunogenicity Research

TIPRANKS
·
Mar 10

Powell Max names Geordan Pursglove chairman and CEO

Reuters
·
Mar 09

Powell Max Limited Successfully Repositions for Its Next Phase of Growth

GlobeNewswire
·
Mar 09

LIXTE Biotechnology (NASDAQ: LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary

TIPRANKS
·
Feb 19

Lixte Subsidiary Liora Technologies Europe Names Sidney Braun CEO

Reuters
·
Feb 18

Lixte Biotechnology Appoints Sidney Braun as CEO of Its Liora Technologies Europe Ltd. Subsidiary

THOMSON REUTERS
·
Feb 18

LIXTE Biotechnology (NASDAQ: LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment

TIPRANKS
·
Feb 10

Improving the Odds: How LIXTE Biotechnology (NASDAQ: LIXT) Is Working to Make Cancer Therapies More Effective

TIPRANKS
·
Feb 06

LIXTE Biotechnology Holdings (NASDAQ: LIXT) Advances a Novel Approach to Enhancing Cancer Therapy

TIPRANKS
·
Jan 24

LIXTE Biotechnology Holdings (NASDAQ: LIXT) Sponsors Good Health Mind, Body and Soul Summit

TIPRANKS
·
Jan 22

Lixte Biotechnology Holdings to Participate in DealFlow Discovery Conference in Atlantic City

Reuters
·
Jan 20

LIXTE Biotechnology Holdings (NASDAQ: LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK

TIPRANKS
·
Jan 09

Lixte Biotechnology Announces Unregistered Share Exchange with Orbit Capital

Reuters
·
Jan 01

Lixte Biotechnology Holdings Inc - Expands Collaboration With University of Texas Md Anderson Cancer Center & GSK for Lb-100

THOMSON REUTERS
·
Dec 23, 2025

Lixte Biotechnology Expands Ovarian Cancer Trial With MD Anderson and GSK

Reuters
·
Dec 23, 2025

Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

GlobeNewswire
·
Dec 18, 2025

Lixte Biotechnology Holdings Inc. held annual shareholder meeting

Reuters
·
Dec 12, 2025

Lixte Biotechnology Holdings Inc. Outlines Strategy to Expand Oncology Platform with Complementary Modalities, Advancing PP2A Inhibitor Development and Integrating Radiotherapy Technologies

Reuters
·
Dec 08, 2025

Lixte Biotechnology Holdings Inc. Outlines Strategy to Advance LB-100 Combination Therapy, Strengthen Financial Foundation, and Support Multi-Year Clinical Development

Reuters
·
Dec 03, 2025

Lixte Biotechnology Acquires Liora Technologies for Growth

TIPRANKS
·
Nov 26, 2025